Who owns NEKTAR THERAPEUTICS (NKTR)? Elite investor 13F holders
2 tracked elite investors reported holding NEKTAR THERAPEUTICS as of 2026-06-30, including 22NW Fund, Anson Funds. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| 22NW Fund | Nektar Therapeutics - US | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 19624638.00 USD | 281115.000000 | Shares | hold | Original filing |
| Renaissance Technologies LLC | NEKTAR THERAPEUTICS | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Anson Funds | Nektar Therapeutics - US | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 2829748.00 USD | 40535.000000 | Shares | — | Original filing |
| Tudor Investment | Nektar Therapeutics - US | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.